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Abstract We have previously developed a rapid, simple
endoscopic method for evaluating gastrin-stimulated max-
imal acid output (the endoscopic gastrin test, EGT). In
EGT, gastric ﬂuid newly secreted over 10 min after gastrin
stimulation is collected under direct endoscopic visualiza-
tion. In this study, employing the EGT, we evaluated the
effect of rebamipide, a cytoprotective anti-ulcer drug, on
gastric mucus secretion. In ten Helicobacter pylori-nega-
tive healthy volunteers, gastric juice was collected by EGT
prior to and after 4-week administration of rebamipide. The
collected gastric juice was subjected to analysis for gastric
mucus output. Total gastric mucin output was signiﬁcantly
increased by 53% by rebamipide administration from
3.2 ± 1.2 mg hexose/10 min to 4.9 ± 2.2 mg hexose/
10 min (P\0.01). Further analysis by ion-exchange
chromatography revealed that rebamipide administration
induced a speciﬁc increase in acidic mucin rich in sialic
acid. Applying EGT, this study demonstrated that
rebamipide administration increased gastric mucus secre-
tion in human.
Keywords Gastric mucus secretion 
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Introduction
Gastric mucus forms a continuous mucus gel layer coating
the entire gastric mucosa and plays an important role in the
gastric defense mechanism against various noxious agents
such as acid, pepsin, and swallowed material [1]. Several
methodshavebeenusedtoevaluategastricmucusinhuman.
Using biopsy specimens, the depth of the adherent mucus
hasbeen assessed occasionallywith the aid ofhistochemical
staining [2–4]. However, this approach allows only quali-
tative assessment of mucus at very focal sites where the
biopsy specimens are taken; hence, it is not possible to
estimate the amount of gastric mucus from the whole
stomach quantitatively. Therefore, many other studies have
undertaken quantitative assessments of gastric mucus using
aspirated gastric juice, which contains a soluble form of
gastric mucus [5–21]. Residual fasting gastric juice aspi-
ratedthroughanendoscopehasbeenusedtoestimategastric
mucus secretion in some studies [5–8] because it is the most
accessible; however, the composition of the ﬂuid is depen-
dent on many variables such as gastric acid and mucus
secretion, and gastric emptying. In addition, contamination
ofthe gastricaspiratebysalivarymucus isinevitableinsuch
an approach [9]. Hence, freshly secreted gastric juice con-
tinuously aspirated using a nasogastric tube under fasting
and gastrin stimulation has been often employed for mucus
analysis [9–21]. Although this approach could provide
quantitative analysis of soluble mucus, the procedure
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gastric juice collectively, and still a part of the secreted ﬂuid
is lost through the pylorus due to the blind aspiration.
We have previously developed a rapid, simple endo-
scopic method for evaluating gastrin-stimulated maximal
acid output (the endoscopic gastrin test, EGT) [22]. In this
method, gastric ﬂuid freshly secreted over 10 min after
gastrin stimulation is collected under direct endoscopic
visualization. EGT enables routine endoscopic examination
and stimulated acid secretory testing simultaneously within
about 15 min. Thus, since freshly secreted gastric juice is
aspirated under direct visualization, precluding both its loss
through the pylorus and contamination with saliva, the
EGT can be employed for prompt, quantitative assessments
of gastric mucus secretion.
Rebamipide is a cytoprotective anti-ulcer drug [23] that
has been found to reduce the rate of recurrence of gastric
ulcers, regardless of the presence or absence of H. pylori
infection [24]. Rebamipide has also been shown to be
effective in preventing nonsteroidal anti-inﬂammatory drug
(NSAID)-induced gastric mucosal injury [25, 26]. Previous
animal studies indicated that one of the principal gastric
defense mechanisms afforded by rebamipide was through
the increase of gastric mucus secretion, probably resulting
from the stimulation of endogenous prostaglandin pro-
duction in the gastric mucosa [27]. However, direct
evidence that the agent can increase gastric mucus secre-
tion in human is lacking, probably due to the technical
difﬁculty in assessing gastric mucus precisely.
In this study, employing the EGT technique to collect
freshly secreted gastric juice, we evaluate the effect of
4-week oral administration of rebamipide on gastric acid
and mucus secretion in healthy volunteers.
Methods
Ten H. pylori-negative healthy volunteers (nine men), all
nonsmokers, with a mean age of 35 years (27–50 years)
were enrolled in this study. Their H. pylori status was
determined by
13C-urea breath test. None of the subjects
were taking any drugs and were found to be normal by
upper gastrointestinal endoscopy. In each subject, two
series of experiments were conducted, at an interval of at
least 4 weeks as the washout period, in a random sequence.
One series comprised EGT prior to and after 4-week
administration of rebamipide, and the other, as controls,
comprised two EGTs at a 4-week interval without any
treatment. One each occasion for EGT, the test was per-
formed in the morning after overnight fast. In the treatment
allocation, rebamipide was administered at a dose of
100 mg three times a day, and the ﬁnal dose of the drug
was taken 2 h before performing EGT.
Gastric Aspiration with the EGT Technique
The details of EGT have been reported previously [22].
Brieﬂy, subjects were injected intramuscularly with penta-
gastrin at a dose of 6 lg/kg (pentagastrin; Sigma, St. Louis,
Mo, USA) about 15 min before the endoscopy. On entering
the stomach with the endoscope, the gastric ﬂuid pooled in
the stomachwas aspirated and discarded. Then, gastric juice
newlysecretedbetween20and30 minafterthepentagastrin
injection was aspirated and collected under direct visuali-
zation during the routine endoscopic examination. During
the examination, the subjects were asked not to swallow
their saliva. After the collection of gastric juice, the endo-
scope was removed. The volume ofgastric juice collected in
the 10-min period was recorded and then the collected
gastric juice was divided, with one half subjected to analysis
for gastric acid secretion and the other used for analysis of
gastric mucus secretion. During the laboratory work the
investigators were blinded to the subjects’ allocation.
Assessment of Gastric Acid Secretion
The H
? concentration of the gastric juice was determined
by titration. Acid output in the 10-min period was calcu-
lated by multiplying the volume by the H
? concentration,
and the EGT value was expressed in units of mEq/10 min.
We have previously shown that EGT values correlate very
well with the peak acid output determined by conventional
methods (correlation coefﬁcient of 0.92) with high repro-
ducibility (coefﬁcient of variation of 5.6%) [22].
Extraction and Isolation of Mucin in Gastric Juice
The collected gastric juice was centrifuged at 1,5009g for
30 min at room temperature to remove the contaminating
debris. The mucin in the gastric juice samples was
extracted and isolated by a previously described method
[28]. This method could successfully isolate and condense
the mucin from the gastric juice, without contamination by
nonmucin glycoproteins such as serum-type glycoproteins.
Absolute ethanol (6 ml) was added to 2 ml of the super-
natant obtained from the gastric juice to make a 75% (v/v)
ethanol concentration. The resultant suspension was
maintained at 4C overnight to complete the precipitation,
after which the precipitate was collected by centrifugation
(8,0009g for 30 min at 4C). The pellet was dissolved in
distilled water (2 ml) and its hexose content was measured
by the phenol-sulfuric acid method. The mucin content of
the gastric juice was expressed as the hexose amount in the
solution obtained by the precipitation method (lg/ml). The
mucin output was determined by multiplying the mucin
concentration by the volume of gastric juice collected in
the 10-min period.
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The mucins were fractionated by ion-exchange chroma-
tography as described previously [5, 6]. The mucin solution
obtained was digested with 1 mg/ml chymotrypsin,
extensively dialyzed against deionized water, lyophilized,
and redissolved in 10 mmol/l Tris–HCl, pH 7.2. The
sample was applied to a 5 9 50 mm ion-exchange column
containing DEAE-Sepharose CL-6B (Phamacia Fine
Chemicals, Sweden) and eluted at 1 ml/min with a dis-
continuous gradient concentration of NaCl (0, 0.25, 0.5,
1.0 mol/l) in 10 mmol/l Tris–HCl, pH 7.2. The efﬂuent
solution was checked by hexose measurement and the
mucin recovery was found to be approximately 90%.
Statistics
Data are expressed as the mean ± standard deviation (SD)
and Student’s paired t test was used to compare the results
between the two studies, either for rebamipide adminis-
tration or for controls. P-value\0.05 was considered to be
statistically signiﬁcant. The study was approved by Tohoku
University School of Medicine Ethics Committee and each
subject gave written informed consent.
Results
The volume of the aspirated samples collected with the
EGT from 40 individual tests in the present study ranged
from 19 to 56 ml, with an average of 37 ml, which was
sufﬁcient for the analysis for both gastric acid and mucus in
each occasion. The overall results for various parameters of
the gastric aspirates collected by EGT are listed in Table 1.
The volume of secreted gastric ﬂuid was not signiﬁcantly
different between prior to and after 4-week administration
of rebamipide (prior to: 35.4 ± 8.1 ml versus after:
33.0 ± 7.3 ml) (Table 1; Fig. 1). Regarding the effects of
rebamipide on gastric acid secretion, the administration did
not signiﬁcantly alter gastric acidity (prior to:
107.4 ± 27.2 mEq/l versus after: 120.0 ± 15.9 mEq/l) nor
total gastric acid output (prior to: 3.8 ± 1.2 mEq/10 min
versus after: 4.0 ± 1.3 mEq/10 min).
In contrast, rebamipide affected gastric mucus secretion
assessed by determination of both the mucin concentration
and total mucin output of gastric aspirates. Both parameters
were increased by rebamipide administration in all but two
subjects. The mean mucin concentration prior to reb-
amipide administration was 93.6 ± 37.8 lg hexose/ml and
was signiﬁcantly increased to 155.8 ± 81.3 after the
Table 1 Changes in various parameters of gastric aspirates collected by the EGT
On rebamipide (n = 10) Drug free (n = 10)
First exam Second exam P value First exam Second exam P value
Secreted volume (ml) 35.4 ± 8.1 33.0 ± 7.3 N.S. 36.6 ± 8.7 38.6 ± 12.5 N.S.
Acidity (mEq/l) 107.4 ± 27.2 120.0 ± 15.9 N.S. 118.3 ± 13.5 116.7 ± 11.9 N.S.
Total acid output (mEq/10 min) 3.8 ± 1.2 4.0 ± 1.3 N.S. 4.3 ± 0.8 4.4 ± 1.2 N.S.
Mucin concentration (lg hexose/ml) 93.6 ± 37.8 155.8 ± 81.3 \0.01 98.4 ± 84.8 89.7 ± 63.5 N.S.
Total mucin output (mg hexose/10 min) 3.2 ± 1.2 4.9 ± 2.2 \0.01 3.5 ± 3.3 3.7 ± 5.5 N.S.
% Of acidic mucin 31.5 ± 7.8 39.6 ± 12.1 \0.05 28.8 ± 12.7 29.4 ± 11.1 N.S.
NS, not signiﬁcant. Data represents mean ± SD
Fig. 1 Changes in volume of
gastric aspirates collected with
the endoscopic gastrin test
(EGT). Gastric aspirates were
collected by EGT prior to and
after 4-week rebamipide
administration (a), or at a
4-week interval without any
treatment (b). There were no
signiﬁcant differences between
the two occasions in either
group. NS, not signiﬁcant
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1234-week administration (P\0.01) (Table 1; Fig. 2). Con-
sequently, total gastric mucin output was signiﬁcantly
increased by 57% by rebamipide administration from a
mean value of 3.2 ± 1.2 mg hexose/10 min pre treatment
to 4.9 ± 2.2 post treatment (P\0.01) (Table 1; Fig. 3).
To examine which constituent of the gastric mucins was
increased by the rebamipide administration, the gastric
mucins extracted from the gastric aspirates were divided
into three fractions (Fr. I, Fr. II, and Fr. III) by ion-
exchange chromatography. Figure 4 shows a typical
DEAE-Sepharose chromatography elution pattern of the
mucins prior to and after rebamipide administration,
revealing that rebamipide administration increased gastric
mucin secretion speciﬁcally by augmenting Fr. III mucin.
We previously reported that these mucin fractions corre-
sponded to compositionally distinct mucin species using
Fig. 2 Changes in gastric
mucin concentration at 4-week
interval by rebamipide (a)o ri n
drug-free controls (b). Gastric
aspirates were collected by EGT
and the amounts of gastric
mucin were deﬁned by the
hexose contents. The gastric
mucus concentration was
signiﬁcantly increased by
rebamipide administration while
it was unchanged in the drug-
free controls. NS, not signiﬁcant
Fig. 3 Changes in gastric mucin output at 4-week interval by
rebamipide (a) or drug-free controls (b). Gastric aspirates were
collected by EGT and the amounts of gastric mucin were deﬁned by
the hexose contents. Gastric mucus output was signiﬁcantly increased
by rebamipide administration whereas it did not change in the drug-
free controls. NS, not signiﬁcant
Fig. 4 A representative case
showing the changes in the
constituents of the gastric mucin
by ion-exchange
chromatography prior to and
after rebamipide administration.
Gastric mucins extracted from
the gastric aspirates were
divided into three fractions
(Fr. I, Fr. II, and Fr. III).
Rebamipide administration
increased speciﬁcally Fr. III
mucin, namely acidic mucin
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123gas-liquid chromatography, and that Fr. III mucin repre-
sented acidic mucin involving much more sialic acid as a
constituent compared with Fr. 1 or Fr. II [5, 6]. Conse-
quently, the percentage of Fr. III, that is, the acidic mucin
in the total mucin content, was signiﬁcantly increased from
32% to 40% by rebamipide administration (P\0.05)
(Table 1; Fig. 5). In one of the two patients who exhibited
a decline in total mucin output on rebamipide (Fig. 3a), the
percentage of acidic mucin was also decreased (Fig. 5a).
In the controls, in which EGT was repeated on two
separate days at a 4-week interval without any treatment,
no parameters analyzed changed between the two occa-
sions (Table 1).
Discussion
Using gastric juice samples collected with the EGT tech-
nique, this study demonstrated that rebamipide, a
cytoprotective anti-ulcer drug, administered at the com-
monly used dosage during 4 weeks, caused a signiﬁcant
increase in gastric mucus secretion while the drug did not
signiﬁcantly modify secretory volume nor gastric acid
secretion. This ﬁnding in human conﬁrms previous obser-
vations from animal studies [27], supporting the view that
one potential mechanism of the anti-ulcer efﬁcacy elicited
by rebamipide administration results from enhancement of
the gastric mucosal defense action by stimulating gastric
mucus secretion.
There are two physical forms of the gastric mucus: one
consists of a thin layer adherent to the gastric mucosa, and
the second component is soluble mucus that contains
mucus cleaved by pepsin degradation [29] or newly
secreted with acid as a separate unit [30]. The adherent
mucus normally covers the gastric mucosa and acts as a
protective physical barrier against noxious luminal agents.
However, since the adherent mucus is not collected by the
aspiration of gastric juice, quantitative assessment of this
material is difﬁcult. Therefore, soluble mucus has been
employed as an index of gastric mucus secretion on the
assumption that it has reached a steady-state relationship
with the adherent mucus. Thus, analysis of soluble mucus
using gastric aspirates has generally been applied to esti-
mate gastric mucus secretion in many studies that have
investigated the effects of various kinds of drugs on gastric
mucus secretion [10–20].
In examining gastric acid secretion, provoking the
maximal gastric secretory state stimulated by pentagastrin
is essential to obtain reproducible results by neglecting
variable effects from other factors. Similarly, stimulation
by pentagastrin is advantageous for examining gastric
mucus secretion as well as lowering the mucus viscosity by
dilution due to the enhanced gastric secretory volume [16].
In addition, pentagastrin, by lowering the gastric luminal
pH, has been reported to function as a strong stimulus for
mucin release from the mucous cells [31, 32], and this
property also facilitates the recovery of gastric mucus and
the correct timing of collections under a pentagastrin-
stimulated condition.
The EGT was devised originally to estimate gastric acid
secretion during endoscopic examination in order to
shorten the conventional time-consuming procedure in
which gastric juice was collected through a nasogastric
tube. In EGT, both facilitated recovery with a stimulant
injection and precise aspiration of gastric juice under direct
endoscopic visualization enable accurate estimation of
gastric acid secretion with high reproducibility, despite the
short duration of the procedure, requiring only 10 min for
collecting the gastric juice [22]. In this study, we applied
the EGT technique for prompt, quantitative analysis of
gastric mucus secretion in human.
Regarding the time course of the gastric mucus secretory
response to a stimulant injection, previous studies indicated
that the response reached a plateau within 30 min of the
injection [14, 17]. Hence, the gastric aspirates obtained at
20–30 min after intramuscular pentagastrin injection, when
the gastric juice is collected with the EGT technique,
represented the peak or near-peak mucus secretory
Fig. 5 Changes in the
percentage of acidic mucin in
total mucin content at 4-week
interval by rebamipide (a)o ri n
drug-free controls (b).
Proportions of acidic mucin
were signiﬁcantly increased by
rebamipide administration while
they did not change in controls.
NS, not signiﬁcant
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123response to the stimulant. In analyzing the reproducibility
of gastric acid and mucus secretion with the EGT technique
based on the present results in controls, the median coef-
ﬁcient of variations was 10.3% (0.7–23.4%) for the gastric
acid secretion while it was 35.6% (3.8–87.3%) for mucus
secretion. The high reproducibility of gastric acid secretion
with the EGT was consistent with our original report
(coefﬁcient of variation 5.6%) [22]. In contrast, the
reproducibility turned out to be rather poor for gastric
mucus secretion, especially in a few cases in which the
differences between the two results was more than a factor
of two. Although, as far as we know, no previous reports
have investigated the reproducibility of gastric mucus
secretion, relatively poor reproducibility might be expected
for such analyses. One possible reason for the lower
reproducibility of gastric mucus analysis compared with
gastric acid is that gastric mucus secretion can be affected
by various factors other than pentagastrin stimulation,
resulting in variable results, while gastric acid can be
maximally stimulated with pentagastrin and therefore tends
to show consistent results. Therefore, in assessing gastric
mucus secretion using gastric aspirates, it is necessary to
take into account its relatively poor reproducibility.
Despite such limitations in estimating the gastric mucus
secretion using aspirated samples, the present study suc-
cessfully demonstrated in human that 4-week rebamipide
administration signiﬁcantly increased the mucin concen-
tration of the gastric aspirate while it did not modify the
secretory volume, resulting in a signiﬁcant increase in total
mucin output. Since previous studies also indicated that
increases in gastric mucus secretion were yielded by
administering other cytoprotective drugs such as miso-
prostol [20] or teprenone [11] in human, this could be a
common feature in this type of agent that contributes to
their anti-ulcer efﬁcacy. Rebamipide elevates gastric
mucus secretion, probably by increasing the generation of
gastric mucosal prostaglandin E2, which is known to be a
strong stimulant for gastric mucus secretion [14]. Hence,
the increase in the soluble mucus yielded by rebamipide
administration in this study is likely to reﬂect an increase in
the newly secreted adherent mucus, which is considered to
be more important as a protective physical barrier of the
gastric epithelium. Although prostaglandin E2, especially
at a higher dose, can function as a potent inhibitor of
gastric acid secretion as well, our present results indicate
that rebamipide, at least at the commonly used dosage,
does not affect gastric acid secretion in human. In this
study, we evaluated the effect of 4-week administration of
rebamipide, which is a commonly recognized treatment
period for gastric ulcers, although shorter administration of
the drug may be sufﬁcient to induce a stimulatory effect on
gastric mucus secretion, as shown in other cytoprotective
drugs [11, 20].
In the present study, rebamipide administration did not
induce any measurable increase in gastric mucus secretion
in three subjects, and they could be nonresponders to the
treatment. It would be intriguing to investigate the link
between the effect of rebamipide on gastric mucus
secretion and the clinical cytoprotective property of the
drug in human. On the other hand, since it has been
reported that rebamipide also exerts cytoprotective effect
through other mechanisms such as free-radical scavenging
or attenuation of neutrophil activity [23], further studies
are required to clarify the precise mechanism of action of
the drug.
Mucin, a highly glycosylated glycoprotein with high
molecular weight, is a major component of gastric mucus.
We previously reported that the human gastric luminal
mucins can be fractionated into three major components
according to the ratio of sialic acid to other carbohydrate
components [5, 6]. Further analysis of the mucin compo-
sition in the present study revealed that the increase in total
mucin output induced by rebamipide administration was
due predominantly to the increase in Fr. III mucin, which
corresponds to acidic mucin rich in sialic acid. This spe-
ciﬁc elevation of a mucin fraction by rebamipide
administration has not been reported in previous studies
utilizing other cytoprotective drugs. The increased total
mucin output elicited by rebamipide administration, and in
particular the elevated fraction of acidic mucin rich in
sialic acid, may have clinical implications for the gastric
mucosal defense mechanism. Sialic acid is linked to the
monosaccharides, giving electronegative charges to the
glycoprotein molecule, a chief constituent of the mucin
structure, and thus the presence of sialic acid residue in
mucins may contribute to enhanced interaction between the
mucins and other chemical species, resulting in facilitated
boundary lubrication and reducing damage to the gastric
mucosa [33]. In addition, the mucus charge elicited by the
presence of sialic acid residues can also contribute to the
high viscosity of mucin, leading to enhancement of the
gastric barrier function [34].
Whether the different fractions of mucins presented in
this study are secreted by different types of epithelial or
glandular cells, or whether all of them are produced by the
same cells in the gastric mucosa, remains to be clariﬁed.
The gastric mucosa has two types of mucin-secreting cells:
surface mucous cells and gland mucous cells [35, 36].
Accumulating evidence suggests that gastric mucins
secreted by distinct types of gastric mucus cells operate
differently in the gastric defensive mechanism [37–40]. A
recent molecular biological approach using a monoclonal
antibody enables quantitative determination of gastric
mucins in human gastric juice that originate from two
distinct types of mucin-secreting cells [41]. Further studies,
combined with such an approach, will help identify the
Dig Dis Sci (2009) 54:1500–1507 1505
123origin of the speciﬁc mucin secretion elicited by reb-
amipide administration and clarify the precise effect of
rebamipide on gastric mucus secretion in relation to the
gastric defense mechanism.
In conclusion, applying the EGT technique for aspirat-
ing gastric juice, this study demonstrated that 4-week
administration of rebamipide at the commonly used dosage
induced an increase in gastric mucus secretion in human
while it did not affect gastric acid secretion. This obser-
vation could contribute to understanding one of the
underlying mechanisms in the cytoprotective anti-ulcer
property of rebamipide. Assessing both gastric acid and
mucus secretion with the EGT technique during routine
endoscopy may provide valuable information regarding the
state of gastric aggressive and defensive factors concur-
rently with endoscopic changes of the gastric mucosa. This
will be particularly useful to evaluate the effect of gas-
tropathy-inducible agents, such as NSAID or aspirin, on the
integrity of the gastric mucosa.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate bar-
rier protection against acid and pepsin. Am J Physiol Cell Physiol.
2005;288:C1–C19.
2. Hidaka E, Ota H, Hidaka H, et al. Helicobacter pylori and two
ultrastructurally distinct layers of gastric mucous cell mucins in
the surface mucous gel layer. Gut. 2001;49:474–480. doi:
10.1136/gut.49.4.474.
3. Sarosiek J, Marshall BJ, Peura DA, Hoffman S, Feng T,
MvCallum RW. Gastroduodenal mucus gel thickness in patients
with Helicobacter pylori: a method for assessment of biopsy
specimens. Am J Gastroenterol. 1991;86:729–734.
4. Jordan N, Newton J, Pearson J, Allen A. A novel method for the
visualization of the in situ mucus layer in rat and human. Clin Sci.
1998;95:97–106. doi:10.1042/CS19980081.
5. Ikezawa T, Ichikawa T, Adachi K, et al. Analysis of mucin
composition in gastric juices of chronic rheumatic patients with
upper gastrointestinal damage. Biomed Res. 2005;26:147–151.
doi:10.2220/biomedres.26.147.
6. Ichikawa T, Koizumi W, Takeuchi H, et al. A new strategy for
evaluation of the eradication treatment of Helicobacter pylori:
validation of the analysis of mucin composition in human gastric
juice. Clin Chim Acta. 2001;303:69–73. doi:10.1016/S0009-
8981(00)00377-6.
7. Marcinkiewicz M,PeuraDA,SarosiekJ.Therelationshipbetween
the content of aggressive and protective components in gastric
juice and endoscopic ﬁndings after naproxen sodium and acet-
aminophenadministration.AmJGastroenterol.1996;91:360–365.
8. Niv Y, Hardy B, Koren R, Rodiomov G, Fraser GM. Association
between gastric acid and mucin secretion in dyspeptic patients.
Digestion. 2002;65:141–148. doi:10.1159/000064934.
9. Pasquier MC, Vatier J, Poitevin C, Vallot T, Mignon M.
Assessment of mucus glycoprotein erosion by measurement of
sialic acid in gastric secretion: Pathophysiologic and therapeutic
aspects. J Clin Gastroenterol. 1991;13(suppl 1):S22–S31. doi:
10.1097/00004836-199112001-00005.
10. Jaworski T, Sarosiek I, Sostarich S, et al. Restorative impact of
rebeprazole on gastric mucus and mucin production impairment
during naproxen administration: its potential clinical signiﬁcance.
Dig Dis Sci. 2005;50:357–365. doi:10.1007/s10620-005-1611-3.
11. Aono M, Moriga M, Mizuta K, Uchino H. Effect of teprenone o
the content of phospholipids in gastric secretion in man. J Gas-
troenterol. 1986;21:454–458.
12. Ene MD, Clamp JR, Roberts CJC. Effects of cimetidine and
carbenoxolone on gastric mucus. Gut. 1988;29:636–641. doi:
10.1136/gut.29.5.636.
13. Baron JH, Barr J, Batten J, Sidebotham R, Spencer J. Acid,
pepsin, and mucus secretion in patients with gastric and duodenal
ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut.
1986;27:486–490. doi:10.1136/gut.27.5.486.
14. Lee SP, Nicholls JF, Robertson AM. Effects of trimoprostil, a
prostaglandin E2 analogue, on human gastric acid secretion and
soluble mucin output. Eur J Clin Invest. 1987;17:1–6. doi:
10.1111/j.1365-2362.1987.tb01217.x.
15. Johansson C, Kollberg B. Stimulation by intragastrically
administered E2 prostaglandins of human gastric mucus output.
Eur J Clin Invest. 1979;9:229–232. doi:10.1111/j.1365-2362.
1979.tb00928.x.
16. Johansson C, Aly A. Stimulation of gastric mucus output by
somatostatin in man. Eur J Clin Invest. 1982;12:37–39. doi:
10.1111/j.1365-2362.1982.tb00937.x.
17. Wilson DE, Levendoglu H, Adams A, Ramsamooj E. A new
PGE1 (CL115, 574)III Effects on gastric acid and mucus secre-
tion in man. Prostaglandins. 1984;28:5–11. doi:10.1016/0090-
6980(84)90109-6.
18. Parodi MC, Molinari F, Barocci S. Inﬂuence of cytoprotective
drugs (Carbenoxolone, Zolomidine, prostanoic acid) on mucus
secretion in patients with gastric ulcer. Scand J Gastroenterol.
1984;19(suppl 92):163–166.
19. Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S,
Saroseik J. Signiﬁcant enhancement of gastric mucin content
after rabeplazole administration Its potential clinical signiﬁcance
in acid-related disorders. Dig Dis Sci. 2003;48:322–328. doi:
10.1023/A:1021983611768.
20. Wilson DE, Quadros E, Rajapaksa T, Adams A, Noar M. Effects
of misoprostol on gastric mucus secretion in man. Dig Dis Sci.
1986;31(suppl 2):126S–129S. doi:10.1007/BF01309336.
21. Molinari F, Parodi MC, De Angelis P, Cheli R. Gsatric mucus
secretion in chronic gastritis. Scand J Gastroenterol. 1984;19
(suppl 92):167–171.
22. Iijima K, Ohara S, Sekine H, et al. A new endoscopic method of
gastric acid secretory testing. Am J Gastroenterol. 1998;93:2113–
2118. doi:10.1111/j.1572-0241.1998.00603.x.
23. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Reb-
amipide: overview of its mechanisms of action and efﬁcacy in
mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(suppl
9):5S–13S.
24. Terano A, Arakawa T, Sugiyama T, et al. Rebamipide, a gastro-
protective and anti-inﬂammatory drug, promotes gastric ulcer
healing following eradication therapy for Helicobacter pylori in a
Japanese population: a randomized, double-blind, placebo-con-
trolled trial. J Gastroenterol. 2007;42:690–693. doi:10.1007/
s00535-007-2076-2.
25. Kim HK, Kim JI, Kim JK, et al. Preventive effects of rebamipide
on NSAID-induced gastric mucosal injury and reduction of gas-
tric mucosal blood ﬂow in healthy volunteers. Dig Dis Sci.
2007;52:1776–1782. doi:10.1007/s10620-006-9367-y.
26. Park SH, Cho CS, Lee OY, et al. Comparison of prevention of
NSAID-induced gastrointestinal complications by rebamipide
1506 Dig Dis Sci (2009) 54:1500–1507
123and misoprostol: a randomized, multicenter, controlled trial-
STORM STUDY. J Clin Biochem Nutr. 2007;40:148–155. doi:
10.3164/jcbn.40.148.
27. Yamazaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric
mucosal protection by OPC-12759, a novel antiulcer compound,
in the rat. Eur J Pharmacol. 1987;142:23–29. doi:10.1016/0014-
2999(87)90649-2.
28. Azuumi Y, Ichikawa T, Ishihara K, Hotta K. The validity of the
ethanol precipitation method for the measurement of mucin
content in human gastric juices and its possible relationship to
gastroduodenal diseases. Clin Chim Acta. 1993;221:219–225.
doi:10.1016/0009-8981(93)90037-5.
29. Pearson JP, Allen A, Venables CW. Gastric mucus: isolation and
polymeric structure of the undegraded glycoprotein: its break-
down by pepsin. Gastroenterology. 1980;78:709–715.
30. Bhaskar KR, Garik P, Turner BS, et al. Viscous ﬁngerprint of
HCl through gastric mucin. Nature. 1992;360:458–461. doi:
10.1038/360458a0.
31. Ichikawa T, Ishihara K, Kusakabe T, et al. Distinct effects of
tetragastrin, histamine, and CCh on rat gastric mucin synthesis
and contribution of NO. Am J Physiol. 1998;274:G138–G146.
32. Scheiman JM, Kraus ER, Boland CR. Regulation of canine
gastric mucin synthesis and phospholipids secretion by acid se-
cretagogues. Gastroenterology. 1992;103:1842–1850.
33. Yusuf S, Nok AJ, Ameh DA, Adelaiye AB, Balogun EO. Cor-
relation of gastric mucosal damage with sialic acid proﬁle in rats:
effect of hydrochloric acid, pepsin and hypertonic saline. Cell
Biochem Funct. 2005;23:339–345. doi:10.1002/cbf.1156.
34. Yakubov GE, Papagiannopoulos A, Rat E, Waigh TA. Charge
and interfacial behavior of short side-chain heavily glycosylated
porcine stomach mucin. Biomacromolecules. 2007;8:3791–3799.
doi:10.1021/bm700721c.
35. Ho SB, Roberton AM, Shekels LL, Lyftogt Ct, Niehans GA.
Toribara NW Expression cloning of gastric mucin complemen-
tarty DNA and localization of mucin gene expression.
Gastroenterology. 1995;109:735–747. doi:10.1016/0016-5085
(95)90380-1.
36. Ota H, Katsuyama T, Ishii K, Nakayama J, Shiozawa T, Tsuka-
hara Y. A dual staining method for identifying mucins of
different gastric epithelial mucous cells. Histochem J. 1991;
23:22–28. doi:10.1007/BF01886504.
37. Goso Y, Ikezawa T, Kurihara M, Endo M, Hotta K, Ishihara K.
Characterization of rat gastric mucins using a monoclonal anti-
body, RGM23, recognizing surface mucous cell-type mucins. J
Biochem. 2003;133:453–460. doi:10.1093/jb/mvg059.
38. Goso Y, Ishihara K, Kurihara M, Sugaya T, Hotta K. Rat gastric
mucins recognized by monoclonal antibodies RGM21 and
HIK1083: Isolation of mucin species characteristic of the surface
and grandular mucosa. J Biochem. 1999;126:375–381.
39. Ikezawa T, Goso Y, Ichikawa T, et al. Appearance of speciﬁc
mucins recognized by monoclonal antibodies in rat gastric mucosa
healing from HCl-induced gastric mucosal damage. J Gastroen-
terol. 2004;39:113–119. doi:10.1007/s00535-003-1261-1.
40. Ota H, Hayama M, Nakayama J, et al. Cell lineage speciﬁcity of
newly raised monoclonal antibodies against gastric mucins in
normal, metaplastic, and neoplastic human tissues and their
application to pathology diagnosis. Am J Clin Pathol. 2001;
115:69–79. doi:10.1309/AMUR-K5L3-M2DN-2DK5.
41. Kubota S, Yamauchi K, Kumagai T, et al. Quantitative deter-
mination of gland mucous cells-type mucin using a monoclonal
antibody, HIK1083: its pathophysiological changes in human
gastric juice. Clin Chim Acta. 2007;377:261–267. doi:
10.1016/j.cca.2006.10.011.
Dig Dis Sci (2009) 54:1500–1507 1507
123